Literature DB >> 3789694

Interferon in the prevention of genital herpes recurrence.

L J Eron, L Harvey, C Toy, D Santomauro.   

Abstract

Patients with genital herpes were treated three times weekly for 12 weeks with 3 X 10(6) IU of alpha 2b interferon (20 patients) or placebo (17 patients) administered by subcutaneous injection in a double-blind trial. Interferon had minimal effects on the suppression of recurrences and moderate toxicity (chills, fever, fatigue, and leukopenia), suggesting that this route and dosage of interferon may not be clinically useful for this indication.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3789694      PMCID： PMC176490          DOI： 10.1128/AAC.30.4.608

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.

Authors:  B M Farr; J M Gwaltney; K F Adams; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

Review 2.  UCLA conference. Interferon: immunobiology and clinical significance.

Authors:  E R Stiehm; L H Kronenberg; H M Rosenblatt; Y Bryson; T C Merigan
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

3.  Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir.

Authors:  S E Straus; H E Takiff; M Seidlin; S Bachrach; L Lininger; J J DiGiovanna; K A Western; H A Smith; S N Lehrman; T Creagh-Kirk
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

4.  Synergism between recombinant human interferon and nucleoside antiviral agents against herpes simplex virus: examination with an automated microtiter plate assay.

Authors:  D M Moran; E R Kern; J C Overall
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

5.  Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root.

Authors:  G J Pazin; J A Armstrong; M T Lam; G C Tarr; P J Jannetta; M Ho
Journal:  N Engl J Med       Date:  1979-08-02       Impact factor: 91.245

6.  A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection.

Authors:  J M Douglas; C Critchlow; J Benedetti; G J Mertz; J D Connor; M A Hintz; A Fahnlander; M Remington; C Winter; L Corey
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

7.  Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice.

Authors:  E B Fraser-Smith; D A Eppstein; Y V Marsh; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

Review 8.  Genital herpes simplex virus infections: clinical manifestations, course, and complications.

Authors:  L Corey; H G Adams; Z A Brown; K K Holmes
Journal:  Ann Intern Med       Date:  1983-06       Impact factor: 25.391

9.  Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients.

Authors:  M S Hirsch; R T Schooley; A B Cosimi; P S Russell; F L Delmonico; N E Tolkoff-Rubin; J T Herrin; K Cantell; M L Farrell; T R Rota; R H Rubin
Journal:  N Engl J Med       Date:  1983-06-23       Impact factor: 91.245

10.  Paradoxical effects of interferon on reactivation of oral infection with herpes simplex virus after microvascular decompression for trigeminal neuralgia.

Authors:  M Ho; G J Pazin; J A Armstrong; H S Haverkos; J S Dummer; P J Jannetta
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226
  10 in total
  2 in total

1.  Therapy of genital herpes with topically applied interferon.

Authors:  L J Eron; C Toy; B Salsitz; R R Scheer; D L Wood; P I Nadler
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections.

Authors:  D I Bernstein; C J Harrison
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.